1-1 of 1
Grant Langdon
Close
Sort by
Journal Articles

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia

Clinical Trials & Observations
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Nichola Cooper, Peter Kiessling, Ute Massow, Franz Woltering, Rose Snipes, Juan Ke, Grant Langdon, James B. Bussel, Stephen Jolles
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4136–4146.
https://doi.org/10.1182/bloodadvances.2020002003
Published: 2020
Includes: Supplemental data